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Abstract
 
 
Multiple myeloma (MM), as one of a variety of 
autoimmune diseases, affects the immune 
system and, on the other hand, is considered to 
be a hematologic impairment. One of the most 
common and important complications of MM is renal 
impairment (RI), which is associated with an 
increase in serum Cr levels. Although RI is one 
of the major complications of MM, the routine 
therapies for MM patients practically lack 
acceptable efficacy for the improvement of RI 
patients, and as a result, RI remains a deadly 
disease with high mortality rate and very bad 
prognosis; therefore, new treatments have been 
proposed for the improvement of nephropathy 
in patients with MM, and extensive research is 
ongoing in various phases, including clinical 
trials. Attempts were made in this study to review 
common and advanced treatments (immuno- 
therapy, cell therapy, new therapies based on 
genetic engineering) in these patients and to 
consider this disease from an immunological 
viewpoint.
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Introduction
The immune system is the body’s natural defense against 
infection and malignant diseases. However, sometimes 
its responses can cause autoimmune diseases (1-7). 
Multiple Myeloma (MM) is one types of autoimmune 
diseases associated with B cells and plasma cells are 
highly proliferated and IgG antibody is produced at high 
levels in serum and urine. It alone accounts for 10% 
of all hematologic malignancies. The disease affects 
people’s immune system and, is also considered as a 
hematological defect. The disease mainly involves the 
elderly (8) so that the average age of people involved 
with MM is 65 years (9). This disease is more common 
in men and the prevalence of this disease in Africa and 
the United States is twice as high as in Europe. One of 
the most common and important complications of MM 
is renal impairment (RI), which is associated with an 
increase in serum creatinine levels. RI is seen in 20-40% 
of patients newly diagnosed with MM (NDMM) and 25% 
of patients (RRMM) and / or refractory multiple myeloma 
with relapsed symptoms and creatinine levels increases 
to above 4 mg/ml  in most people with this condition (10). 
MM begins with acute kidney injury (AKI), and recurrence 
is associated with nephropathy casts.
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Prevalence of RI in patients with MM
RI is seen in half of the patients with MM. Severe RI is also 
seen in more than 15% of these patients. Table 1 presents 
the prevalence of all types of disorders involved in this 
disease.
Today for prevention and treatment most disorders such 
as urinary system dysfunctions have been evaluated and 
new drugs and methods and their outcomes have been 
considered (11-19). Since routine therapies for patients 
with MM have virtually no acceptable efficacy for the 
improvement of RI patients and RI is still considered as a 
disease with high mortality and very bad prognosis; new 
treatments have been proposed for the improvement of 
nephropathy in patients with MM. In this study, attempts 
were made to review common and advanced treatments 
(immunotherapy, -cell therapy and new therapies based 
on genetic engineering) and discuss this disease from an 
immunological viewpoint.
Mechanisms of nephropathy symptoms in 
patients with MM
Renal damages in patients with MM mostly occur due to 
the toxic effect of the free light chain (FLC). Light chains 
are proteins produced by plasma cells. Within a plasma 
cell, two light chains and two heavy chains are combined 
to form an immunoglobulin. The free light chain is filtered 
through the glomeruli and is removed and catabolized 
by the cells of the proximal tubule cells (PTCs). The FLC 
level in the serum of patients with MM can be increased 
up to 100 times, which indicates the high ability of PTCs 
cells in absorbing and catabolizing these proteins, which, 
as a result of increased activity of these cells, leads to an 
increase in the concentration of FLC in the urine and fluid 
in the tubule of the kidney(20). Urinary FLC has a high 
affinity for binding to the carbohydrate portion of (THP), 
which causes aggregates that cause cysts and blockage of 
renal tubules(21). FLC can activate inflammatory pathways 
and cause fibrosis in the tubular area during inflammation 
in cells in the tubule (20). Also, various factors, including 
nonsteroidal anti-inflammatory compounds, dehydration, 
acidosis, and angiotensin converting enzyme (ACE) 
inhibitors interfere with the onset of RI and contribute to the 
nephropathy caused by FLC. On the other hand, factors 
like hypercalcium may further aggravate the symptoms of 
nephropathy (10, 22, 23)(Figure 1).
 MM therapies
1. Common MM Therapies:
1-1 Primary Care Support
In case of transient but recurrent defects in the kidney, 
especially in people who excrete plenty of Bence Jones 
protein, immediate supportive treatments have been 
taken for patients for whom combination of bortezomib 
and dexamethasone is a good therapeutic option. And in 
limited cases, thalidomide is also prescribed. Lenalidomide 
is another low-dose drug that can control and treat the 
symptoms of nephropathy in patients with MM(24). In 
addition, plasma replacement has been suggested as a 
treatment for nephropathy in patients with MM. However, 
the use of this treatment is controversial in RI people 
suffering from excretion of Bence Jones protein.
1-2. Corticosteroids (dexamethasone) and conventional 
chemotherapy
Dexamethasone is one of the cortical derivatives that plays 
an important role in improving nephropathy in patients with 
MM. A high dose of dexamethasone leads to a higher rate 
of kidney regeneration activity in MM patients who have 
recently suffered RI. It is also prescribed, independently 
of dialysis, for patients with kidney complications and 
high risk of severe proteinuria, which discharges Bence 
Jones at high levels in the urine (25). In addition, the new 
drug combination of thalidomide+bortezomib is safe in 
the treatment of nephropathy in patients with MM, leading 
to renal function improvement. However, the use of 
dexamethasone and chemotherapy is recommended for 
effective treatment of nephropathy in these individuals (25-
27).
2. New treatments and advanced drugs:
Over the last decade, there has been a major advance in 
MM treatment and new and advanced therapies were later 
used for the treatment of transplant recipients as well as 
those who were not eligible for transplantation (28) and 
considering their effectiveness, the probability of complete 
responses (CR), progression of disease, disease-free 
survival (PFS) and total survival (OS) have been increased. 
Combined therapeutic approaches, including dietary 
regimens and chemotherapy, have been proposed as a 
standard treatment approach, which can be done in both 
the ASCT patients as well as patients who do not intend 
organ transplants(29). The new therapeutic approaches 
and advanced drugs that are introduced and presented in 
this effort are presented in more detail as follows.
RE VIE W ARTICLE
Table 1: Prevalence of some types of defects and RI in patients with MM 
MIDDLE EAST JOURNAL OF FAMILY MEDICINE  •  VOLUME 7 , ISSUE 10 97
WORLD FAMILY MEDICINE/MIDDLE EAST JOURNAL OF FAMILY MEDICINE VOLUME 15 ISSUE 7, SEPTEMBER 2017
RE VIE W ARTICLE
Figure 1: Mechanisms involved in RI-caused MM
Renal impairment: RI; Free light chain: FLC; Proximal tubule cells = PTCs; Angiotensin converting enzyme: ACE.
Table 2: New anti- MM drugs the mechanism of action of which is proteasome inhibition
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2.1 Proteasome inhibitors
Proteasome inhibitors have been able to significantly 
advance the progression of MM disease independently of 
organ transplants. Some of the new anti-MM drugs, the 
mechanism of action of which is proteasome inhibition are 
listed in Table 2 (previous page).
2-2 Immunomodulatory drugs
Immunomodulatory drugs (IMiDS) directly affect multiple 
myeloma cells and bone marrow environments, leading 
to changes in cytokines, inhibition of angiogenesis, and 
increased number and function of various cells, including 
T, NK, and NKT. IMiDs are also capable of replicating Treg 
cells. In addition, IMiDs can enhance the ADCC defense 
response in NK cells by increasing expression of FasL and 
granzymes. Considering this feature, IMiDs can be used 
in targeted therapies for immunotherapy(39). As indicated 
in the mechanism section, inflammatory response is one 
of the effective factors in the progression and treatment 
process. Therefore, this group of drugs can effectively 
and potentially contribute to the treatment of MM patients 
(Table 3). Given that immunomodulators include a wide 
range of therapeutic strategies, some of the most recent 
and most important ones are mentioned here, and some 
of them are listed in Table 3.
2-2-1 - Bispecific T cell engages (Bi-TEs)
BiTEs are a novel immunotherapy approach in relation to 
antibodies and T cells. This method enables us to design 
antibodies using genetic engineering, which is in contrast 
to the usual dual specificity. For example, the antibody is 
designed in such a way that, on the one hand, as a specific 
marker of T lymphocytes for CD3 and as a specific marker 
for CD19 on the surface of the cells of the lymphoma, 
on the other hand. Thus, a tumor cell with T lymphocyte 
(as the main anti-tumor cell) will be placed next to each 
other, resulting in the destruction of tumor cells at higher 
intensity. BiTEs have been investigated for the treatment 
of melanoma in vitro and in vivo and satisfactory results 
were also obtained.
2-2-2 Adoptive T cell Therapies (ACT)
In this method, the T-cell of a person with MM is isolated 
from its whole blood, and these cells lead to the activation 
and development of T-cells in the presence of anti-CD3-
CD28 beads and IL2 in the ex-vivo environment and after 
being discharged from the bone marrow from the myeloid 
line and the autologous transplantation, this ex-vivo 
amplified compound is inoculated and leads to primary 
lymphocytosis. Recently, this method has also been used 
for the first time in the production of bone marrow infiltrated 
t lymphocytes (mILs) as clinical anti-tumor immunity (40). 
The results of this treatment are satisfactory, but more 
confirmation is needed in this regard.
2-2-3 TCR transgenic T cells
In this method, TCR infusion occurs with high affinity and 
common peptide antigens between two types of cancer 
(NY-ESO-1, LAGE-1)(41). Initial laboratory tests indicate 
that the infusion T cell, the function of which is actively 
maintained, occurs and these cells remain active in the 
body and in the presence of IL2 without fatigue for up 
to one year. On the other hand, all people with MM are 
being treated to respond to HLA-dependent treatment. 
Nevertheless, these cells are HLA-dependent and 
therefore, this is a therapeutic constraint compared to the 
CART method(25).
2-2-4 BTK inhibitors
Bruton Tyrosine kinase is an enzyme from the Tec 
family that is expressed in hematopoietic cells such 
as B and myeloid cells, mast cells, and platelets, and 
plays a key role in several important cellular processes, 
including differentiation, proliferation, cell migration and 
apoptosis(42, 43). In the case of mutation in the BTK 
gene, the maturation of these cells is impaired and genetic 
and hereditary diseases such as XLA (X-linked gamma-
globulinemia) are created(44). On the other hand, the 
excessive activity of BTK refers to the neoplasm associated 
with B cells(45). Ibrutinib is one of the drugs produced in 
this field and is capable of inhibiting the function of this 
enzyme during the binding of covalent to BTK and its 
administration alone or in combination with other drugs 
can provide satisfactory therapeutic results. In a study in 
2015, a combination of Ibrutinib and Carfilzomib with or 
without dexamethasone was used to treat RRMM patients 
and a target response rate of 62% was reported(46). The 
effect of BTK expression in the treatment of the disease 
is so important that there are many solutions to inhibit the 
expression of this enzyme, which can have a significant 
effect on the treatment process.
2-3- Monoclonal Antibodies
Therapies performed based on monoclonal antibodies 
against target antigen have been defeated due to the 
lack of clear expression of the target molecule on the 
plasma cells. In fact, early studies have only shown the 
minimal activity of anti-CD20, which is expressed in 20% 
of plasma cells. Studies have also been conducted on 
several other monoclonal antibodies (anti [TRAIL-R1, 
IL6, CD38, CD138, CD74, CS1, CD56, IGF-1R, CD40]), 
among which two monoclonal antibodies, Elotuzumab and 
Daratuzumab, is important and practical in MM disease 
(Table 4). In addition, B cell maturation antigen (BCMA) 
antibodies are under construction and its clinical trial is 
in progress. BCMA, a superfamily protein TNFR, is used 
as an important target in the construction of monoclonal 
antibodies and can be of great help in treating patients 
with MM. On the other hand, the production of antibodies 
against CD138, CD56 and CD74 is also under investigation 
in the early stages of clinical practice (25).
2-4 High-dose therapy and autologous stem cell 
transplantation (HDT & ASCT)
ASCT (Post-autologous Stem Cell Transplant Therapy) is 
one of the supportive therapies that is used for MM patients 
during a 12-month period (63-66), leading to improved OS 
and better treatment outcomes) during the transplantation 
process. The ASCT method is applicable to all eligible 
MM patients. In this therapeutic approach, following a 
stem cell transplant, 3-4 courses of the drug regimen, 
including bortezomib and dexamethasone in combination 
RE VIE W ARTICLE
MIDDLE EAST JOURNAL OF FAMILY MEDICINE  •  VOLUME 7 , ISSUE 10 99
WORLD FAMILY MEDICINE/MIDDLE EAST JOURNAL OF FAMILY MEDICINE VOLUME 15 ISSUE 7, SEPTEMBER 2017
RE VIE W ARTICLE
Table 3: Some immunomodulatory drugs for the treatment of multiple myeloma
 
Table 4: Monoclonal antibodies approved by the FDA for patients with MM
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with lenalidomide, thalidomide, or cyclophosphamide, 
is received by the patient(67). The administration of this 
therapeutic approach helps patients maintain their condition 
for a progressive free survival (PFS)(68, 69). In addition, 
bortezomib’s mechanism of action, which is to inhibit 
proteasome, helps to create better PFS in MM patients 
with intermediate and high-risk; however, the post-ASCT 
administration of this drug compared with thalidomide, 
which has toxic effects in the blood, offers better treatment 
outcomes. Since the relapse of the disease occurs almost 
entirely in MM patients, the relapse period can be changed 
from 2.5 years to 4 years (70, 71).
2.5 Plasma exchange
The kappa and lambda chains of FLC, which have a 
molecular weight of 45KD and 22.5KD, respectively, are 
excreted from the renal glomeruli after a half-life of 3 and 
6 hours. Consequently, anti-myeloma effects are induced 
in individuals through the “plasma replacement” and FLC 
levels are also reduced. Interestingly, patients who receive 
this treatment are protected against other kidney injuries that 
may occur in the future (72). Additionally, the combination 
of plasma replacement therapy with bortezomib-based 
therapies gives rise to strong responses in all NDMM and 
RRMM patients (73). Plasma replacement in the short term 
leads to the purification of proteins in the extravascular 
part, but in any case, the plasma replacement in the long 
run leads to the purification of other essential proteins; 
therefore, the use of membranes have cut-off for higher 
molecular weight proteins, can be a remedy in this case 
(74).
2.6 Renal transplantation
One of the treatment methods for MM patients involved 
with RI is renal transplantation, which can be used as 
a treatment alternative for these patients, due to the 
increasing number of patients. The results of a study 
which was conducted on 166 patients in 2013 showed that 
the risks of immunosuppression should be considered in 
those who received ASCT and kidney allograft transplants, 
and eventually 26 of them survived without the need for 
dialysis (10, 75). 
2.7 Histone deacetylases (HDACs)
HDACs deacetylates lysine residues (tails) in both histone 
and non-histone proteins. This enzyme in the chromatin 
structure creates a local relaxation and regulates the specific 
expression of the gene. HDACs acts nonspecifically and 
can deacetylate non-histone proteins that is also intended 
to alter the activity and sustainability of their activity, so the 
inhibitory effect of this enzyme complex on the treatment 
of multiple myeloma is very important (76) and specifically 
the combination of inhibitors of HDACs and proteasome or 
immunomodulatory drugs play a very important role in the 
progression of this disease in pre-clinic and clinical phases. 
However, clinical studies that are performed using selective 
HDACs inhibitors reduce the side effects of treatment, 
which leads to increased tolerance in patients and has no 
negative effect on the multiple myeloma activity; therefore 
satisfactory outcomes were obtained when this treatment 
was performed (77). Panobinostat is a deacetylase inhibitor 
that can produce better treatment outcomes in combination 
with dexamethasone and bortezomib. Inhibiting HDACs 
activity leads to an increase in acetylated histone proteins, 
as a result of this epigenetic change, eventually during 
the formation of the chromatin regimen results in the 
activation of the transcriptional process in individuals (78, 
79). Vorinostat is another oral deacetylase inhibitor that 
is effective in treating cutaneous T-cell lymphoma (CTCL) 
(80). Therefore, both panobinostat and vorinostat are 
involved during the inhibition of deacetylation in treatment 
of multiple myeloma. The panobinostat is so important 
in the treatment of these patients that it is prescribed in 
combination with dexamethasone and bortezomib for 
RRMM patients who have received at least two therapy 
y lines in the past (80, 81)and have shown resistance 
and this therapeutic pattern was approved by the FDA in 
February 2015.
Conclusion
Multiple myeloma is a hematologic malignancy that alone 
accounts for 10% of all hematologic malignancies. One of 
the main complications of the disease, which is seriously 
problematic, is high mortality and a lack of satisfactory 
effect of the common treatments intended for this group 
of patients. So, in the last decade, extensive researches 
and studies have been carried out to produce new drugs; 
therefore, many drugs could help with the treatment of 
patients with multiple myeloma by obtaining approval 
from the FDA. Meanwhile, drugs that affect the immune 
system of the human body, namely immunotherapies, are 
extremely important.
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